LXEO Stock News & Catalysts

FEATURED

Lexeo Therapeutics to Present Multiple Oral and Poster Presentations at Key Scientific Conferences in November

Presentations at AHA to highlight Lexeo's cardiovascular gene therapy pipeline, including preclinical programs in desmoplakin and TNNI3 cardiomyopathies New LX2006 data to be presented at ICAR demonstrating cardiac

Summary

Nov 2, 2026, 7:00 AM ·Globe Newswire

RECENT

Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM

NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that it will host an

Oct 19, 2026, 7:00 AM ·Globe Newswire

Lexeo Therapeutics to Participate in the Chardan Healthcare Conference

NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will

Oct 8, 2026, 7:00 AM ·Globe Newswire

Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)

Oral presentation will highlight previously reported data demonstrating early stabilization or improvement in mFARS scores among LX2006-treated participants compared with propensity-matched control cohort from UNIFAI

Oct 1, 2026, 9:00 AM ·Globe Newswire

Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia

NEW YORK, Sept. 23, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, will provide Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a

Sep 23, 2026, 8:00 AM ·PRNewswire

Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company

Sep 23, 2026, 7:00 AM ·Globe Newswire

Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia

Acquisition of Mantle Therapeutics will add multiple new modalities designed to increase or replace frataxin in the brain Collaborations launched to evaluate gene therapy sequential dosing following treatment with

Sep 22, 2026, 7:00 AM ·Globe Newswire

Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO) a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that

Sep 2, 2026, 7:00 AM ·Globe Newswire

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated SUNRISE-FA 2 with first patient enrolled

Aug 12, 2026, 7:00 AM ·Globe Newswire

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy

RMAT designation granted based on recent interim clinical data from ongoing Phase I/II clinical trial evaluating LX2020 for PKP2-ACM LX2020 now holds RMAT, Orphan Drug and Fast Track designations by the FDA NEW YORK,

Aug 5, 2026, 7:00 AM ·Globe Newswire

Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies SUNRISE-FA 2 pivotal study for LX2006 on track to initiate in Q2 2026 with topline

Jun 17, 2026, 4:01 PM ·Globe Newswire

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, inclusion criteria focused on abnormal baseline LVMI and open-label trial design BLA supportive manufacturing strategy

Jun 15, 2026, 7:00 AM ·Globe Newswire

Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that

May 19, 2026, 7:00 AM ·Globe Newswire

Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights

SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026; Awaiting final FDA feedback Multiple presentations highlighting progress across cardiac genetic medicine pipeline and

May 11, 2026, 7:00 AM ·Globe Newswire

Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that

Apr 27, 2026, 5:15 PM ·Globe Newswire

Lexeo Therapeutics, Inc. Common Stock LXEO · News